ID   C43BP_HUMAN             Reviewed;         624 AA.
AC   Q9Y5P4; A8K7S2; B3KUB7; Q53YV1; Q53YV2; Q96Q85; Q96Q88; Q9H2S7;
AC   Q9H2S8;
DT   15-MAY-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   15-MAR-2017, entry version 153.
DE   RecName: Full=Collagen type IV alpha-3-binding protein;
DE   AltName: Full=Ceramide transfer protein;
DE            Short=hCERT;
DE   AltName: Full=Goodpasture antigen-binding protein;
DE            Short=GPBP;
DE   AltName: Full=START domain-containing protein 11;
DE            Short=StARD11;
DE   AltName: Full=StAR-related lipid transfer protein 11;
GN   Name=COL4A3BP; Synonyms=CERT, STARD11;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHARACTERIZATION.
RX   PubMed=10212244; DOI=10.1074/jbc.274.18.12642;
RA   Raya A., Revert F., Navarro S., Saus J.;
RT   "Characterization of a novel type of serine/threonine kinase that
RT   specifically phosphorylates the human goodpasture antigen.";
RL   J. Biol. Chem. 274:12642-12649(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=11007769; DOI=10.1074/jbc.M002769200;
RA   Raya A., Revert-Ros F., Martinez-Martinez P., Navarro S., Rosello E.,
RA   Vieites B., Granero F., Forteza J., Saus J.;
RT   "Goodpasture antigen-binding protein, the kinase that phosphorylates
RT   the Goodpasture antigen, is an alternatively spliced variant
RT   implicated in autoimmune pathogenesis.";
RL   J. Biol. Chem. 275:40392-40399(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, DOMAIN, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=14685229; DOI=10.1038/nature02188;
RA   Hanada K., Kumagai K., Yasuda S., Miura Y., Kawano M., Fukasawa M.,
RA   Nishijima M.;
RT   "Molecular machinery for non-vesicular trafficking of ceramide.";
RL   Nature 426:803-809(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Lung, and Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-77.
RA   Ogi T., Yamamoto Y., Ohmori H.;
RT   "Homo sapiens genomic sequence, containing DINB1 and GPBP gene.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [10]
RP   INTERACTION WITH VAPA AND VAPB, SUBCELLULAR LOCATION, AND MUTAGENESIS
RP   OF ASP-324.
RX   PubMed=16895911; DOI=10.1074/jbc.M605032200;
RA   Kawano M., Kumagai K., Nishijima M., Hanada K.;
RT   "Efficient trafficking of ceramide from the endoplasmic reticulum to
RT   the Golgi apparatus requires a VAMP-associated protein-interacting
RT   FFAT motif of CERT.";
RL   J. Biol. Chem. 281:30279-30288(2006).
RN   [11]
RP   PHOSPHORYLATION AT SER-132, FUNCTION, AND MUTAGENESIS OF SER-132.
RX   PubMed=17591919; DOI=10.1083/jcb.200612017;
RA   Fugmann T., Hausser A., Schoeffler P., Schmid S., Pfizenmaier K.,
RA   Olayioye M.A.;
RT   "Regulation of secretory transport by protein kinase D-mediated
RT   phosphorylation of the ceramide transfer protein.";
RL   J. Cell Biol. 178:15-22(2007).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   PHOSPHORYLATION BY CSNK1G2/CK1.
RX   PubMed=19005213; DOI=10.1091/mbc.E08-07-0669;
RA   Tomishige N., Kumagai K., Kusuda J., Nishijima M., Hanada K.;
RT   "Casein kinase I{gamma}2 down-regulates trafficking of ceramide in the
RT   synthesis of sphingomyelin.";
RL   Mol. Biol. Cell 20:348-357(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-126; TYR-372; SER-373
RP   AND SER-380, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   INVOLVEMENT IN MRD34, AND VARIANT MRD34 LEU-132.
RX   PubMed=25533962; DOI=10.1038/nature14135;
RG   Deciphering Developmental Disorders Study;
RT   "Large-scale discovery of novel genetic causes of developmental
RT   disorders.";
RL   Nature 519:223-228(2015).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 347-624 IN COMPLEXES WITH
RP   CERAMIDES AND DIACYLGLYCEROL, MUTAGENESIS OF GLU-472; GLN-493 AND
RP   ASN-530, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18184806; DOI=10.1073/pnas.0709191105;
RA   Kudo N., Kumagai K., Tomishige N., Yamaji T., Wakatsuki S.,
RA   Nishijima M., Hanada K., Kato R.;
RT   "Structural basis for specific lipid recognition by CERT responsible
RT   for nonvesicular trafficking of ceramide.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:488-493(2008).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.66 ANGSTROMS) OF 347-624 IN COMPLEXES WITH
RP   CERAMIDE AND INHIBITOR, MUTAGENESIS OF TRP-499, AND FUNCTION.
RX   PubMed=20036255; DOI=10.1016/j.jmb.2009.12.029;
RA   Kudo N., Kumagai K., Matsubara R., Kobayashi S., Hanada K.,
RA   Wakatsuki S., Kato R.;
RT   "Crystal structures of the CERT START domain with inhibitors provide
RT   insights into the mechanism of ceramide transfer.";
RL   J. Mol. Biol. 396:245-251(2010).
RN   [21]
RP   VARIANT CYS-138.
RX   PubMed=23033978; DOI=10.1056/NEJMoa1206524;
RA   de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G.,
RA   Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P.,
RA   Gilissen C., del Rosario M., Hoischen A., Scheffer H., de Vries B.B.,
RA   Brunner H.G., Veltman J.A., Vissers L.E.;
RT   "Diagnostic exome sequencing in persons with severe intellectual
RT   disability.";
RL   N. Engl. J. Med. 367:1921-1929(2012).
CC   -!- FUNCTION: Shelters ceramides and diacylglycerol lipids inside its
CC       START domain and mediates the intracellular trafficking of
CC       ceramides and diacylglycerol lipids in a non-vesicular manner.
CC       {ECO:0000269|PubMed:14685229, ECO:0000269|PubMed:17591919,
CC       ECO:0000269|PubMed:18184806, ECO:0000269|PubMed:20036255}.
CC   -!- SUBUNIT: Interacts with COL4A3. Interacts with VAPA and VAPB.
CC       Interaction with VAPB is less efficient than with VAPA.
CC       {ECO:0000269|PubMed:16895911}.
CC   -!- INTERACTION:
CC       Q9H568:ACTL8; NbExp=3; IntAct=EBI-739994, EBI-10306917;
CC       Q15041:ARL6IP1; NbExp=3; IntAct=EBI-739994, EBI-714543;
CC       P78368:CSNK1G2; NbExp=4; IntAct=EBI-739994, EBI-748380;
CC       Q13352:ITGB3BP; NbExp=4; IntAct=EBI-739994, EBI-712105;
CC       P32856-2:STX2; NbExp=4; IntAct=EBI-11156432, EBI-11956649;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16895911,
CC       ECO:0000269|PubMed:18184806}. Golgi apparatus
CC       {ECO:0000269|PubMed:14685229, ECO:0000269|PubMed:16895911,
CC       ECO:0000269|PubMed:18184806}. Endoplasmic reticulum
CC       {ECO:0000269|PubMed:16895911, ECO:0000269|PubMed:18184806}.
CC       Note=Preferentially localized to the Golgi apparatus.
CC       {ECO:0000305|PubMed:16895911}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=CERTL;
CC         IsoId=Q9Y5P4-1; Sequence=Displayed;
CC       Name=2; Synonyms=Delta26, GPBPD26;
CC         IsoId=Q9Y5P4-2; Sequence=VSP_006276;
CC       Name=3;
CC         IsoId=Q9Y5P4-3; Sequence=VSP_041022;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- DOMAIN: The START domain recognizes ceramides and diacylglycerol
CC       lipids, interacts with membranes, and mediates the intermembrane
CC       transfer of ceramides and diacylglycerol lipids.
CC       {ECO:0000269|PubMed:14685229}.
CC   -!- DOMAIN: The PH domain targets the Golgi apparatus.
CC       {ECO:0000269|PubMed:14685229}.
CC   -!- DOMAIN: The FFAT motif is required for interaction with VAPA and
CC       VAPB. {ECO:0000269|PubMed:14685229}.
CC   -!- PTM: Phosphorylation on Ser-132 decreases the affinity toward
CC       phosphatidylinositol 4-phosphate at Golgi membranes and reduces
CC       ceramide transfer activity. Inactivated by hyperphosphorylation of
CC       serine residues by CSNK1G2/CK1 that triggers dissociation from the
CC       Golgi complex, thus down-regulating ER-to-Golgi transport of
CC       ceramide and sphingomyelin synthesis.
CC       {ECO:0000269|PubMed:17591919, ECO:0000269|PubMed:19005213}.
CC   -!- DISEASE: Mental retardation, autosomal dominant 34 (MRD34)
CC       [MIM:616351]: A form of mental retardation, a disorder
CC       characterized by significantly below average general intellectual
CC       functioning associated with impairments in adaptive behavior and
CC       manifested during the developmental period.
CC       {ECO:0000269|PubMed:25533962}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- CAUTION: Was originally reported to have a protein kinase activity
CC       and to phosphorylate on Ser and Thr residues the Goodpasture
CC       autoantigen (in vitro). {ECO:0000305|PubMed:10212244}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF136450; AAD30288.1; -; mRNA.
DR   EMBL; AF232930; AAG42046.1; -; mRNA.
DR   EMBL; AF232935; AAG42051.1; -; Genomic_DNA.
DR   EMBL; AY453385; AAR26717.1; -; mRNA.
DR   EMBL; AY453386; AAR26718.1; -; mRNA.
DR   EMBL; AK091851; BAC03762.1; -; mRNA.
DR   EMBL; AK096854; BAG53379.1; -; mRNA.
DR   EMBL; AK292087; BAF84776.1; -; mRNA.
DR   EMBL; AC008897; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC112183; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC116341; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471084; EAW95757.1; -; Genomic_DNA.
DR   EMBL; CH471084; EAW95760.1; -; Genomic_DNA.
DR   EMBL; BC000102; AAH00102.1; -; mRNA.
DR   EMBL; AB036934; BAB58974.1; -; Genomic_DNA.
DR   EMBL; AB036936; BAB58977.1; -; Genomic_DNA.
DR   CCDS; CCDS4028.1; -. [Q9Y5P4-1]
DR   CCDS; CCDS4029.1; -. [Q9Y5P4-2]
DR   CCDS; CCDS47235.1; -. [Q9Y5P4-3]
DR   RefSeq; NP_001123577.1; NM_001130105.1. [Q9Y5P4-3]
DR   RefSeq; NP_005704.1; NM_005713.2. [Q9Y5P4-1]
DR   RefSeq; NP_112729.1; NM_031361.2. [Q9Y5P4-2]
DR   RefSeq; XP_006714576.1; XM_006714513.2. [Q9Y5P4-1]
DR   RefSeq; XP_016864408.1; XM_017008919.1. [Q9Y5P4-2]
DR   UniGene; Hs.270437; -.
DR   PDB; 2E3M; X-ray; 2.20 A; A=347-624.
DR   PDB; 2E3N; X-ray; 1.40 A; A=347-624.
DR   PDB; 2E3O; X-ray; 1.55 A; A=347-624.
DR   PDB; 2E3P; X-ray; 1.40 A; A/B=347-624.
DR   PDB; 2E3Q; X-ray; 2.08 A; A=347-624.
DR   PDB; 2E3R; X-ray; 1.65 A; A/B=347-624.
DR   PDB; 2E3S; X-ray; 1.94 A; A=347-624.
DR   PDB; 2RSG; NMR; -; A=24-117.
DR   PDB; 2Z9Y; X-ray; 1.80 A; A=347-624.
DR   PDB; 2Z9Z; X-ray; 1.74 A; A=347-624.
DR   PDB; 3H3Q; X-ray; 2.00 A; A/B=347-624.
DR   PDB; 3H3R; X-ray; 1.85 A; A/B=347-624.
DR   PDB; 3H3S; X-ray; 1.66 A; A/B=347-624.
DR   PDB; 3H3T; X-ray; 2.40 A; A/B=347-624.
DR   PDB; 4HHV; X-ray; 1.75 A; A/B=20-121.
DR   PDBsum; 2E3M; -.
DR   PDBsum; 2E3N; -.
DR   PDBsum; 2E3O; -.
DR   PDBsum; 2E3P; -.
DR   PDBsum; 2E3Q; -.
DR   PDBsum; 2E3R; -.
DR   PDBsum; 2E3S; -.
DR   PDBsum; 2RSG; -.
DR   PDBsum; 2Z9Y; -.
DR   PDBsum; 2Z9Z; -.
DR   PDBsum; 3H3Q; -.
DR   PDBsum; 3H3R; -.
DR   PDBsum; 3H3S; -.
DR   PDBsum; 3H3T; -.
DR   PDBsum; 4HHV; -.
DR   ProteinModelPortal; Q9Y5P4; -.
DR   SMR; Q9Y5P4; -.
DR   BioGrid; 115396; 26.
DR   IntAct; Q9Y5P4; 20.
DR   MINT; MINT-1441568; -.
DR   STRING; 9606.ENSP00000369862; -.
DR   BindingDB; Q9Y5P4; -.
DR   ChEMBL; CHEMBL3399913; -.
DR   SwissLipids; SLP:000000407; -.
DR   iPTMnet; Q9Y5P4; -.
DR   PhosphoSitePlus; Q9Y5P4; -.
DR   BioMuta; COL4A3BP; -.
DR   DMDM; 20978413; -.
DR   EPD; Q9Y5P4; -.
DR   PaxDb; Q9Y5P4; -.
DR   PeptideAtlas; Q9Y5P4; -.
DR   PRIDE; Q9Y5P4; -.
DR   Ensembl; ENST00000261415; ENSP00000261415; ENSG00000113163. [Q9Y5P4-2]
DR   Ensembl; ENST00000380494; ENSP00000369862; ENSG00000113163. [Q9Y5P4-3]
DR   Ensembl; ENST00000405807; ENSP00000383996; ENSG00000113163. [Q9Y5P4-1]
DR   GeneID; 10087; -.
DR   KEGG; hsa:10087; -.
DR   UCSC; uc003kds.4; human. [Q9Y5P4-1]
DR   CTD; 10087; -.
DR   DisGeNET; 10087; -.
DR   GeneCards; COL4A3BP; -.
DR   HGNC; HGNC:2205; COL4A3BP.
DR   HPA; HPA035645; -.
DR   HPA; HPA042608; -.
DR   MalaCards; COL4A3BP; -.
DR   MIM; 604677; gene.
DR   MIM; 616351; phenotype.
DR   neXtProt; NX_Q9Y5P4; -.
DR   OpenTargets; ENSG00000113163; -.
DR   PharmGKB; PA26720; -.
DR   eggNOG; KOG1739; Eukaryota.
DR   eggNOG; ENOG410XQTB; LUCA.
DR   GeneTree; ENSGT00650000093230; -.
DR   HOVERGEN; HBG050753; -.
DR   InParanoid; Q9Y5P4; -.
DR   KO; K08283; -.
DR   OMA; SHALWPE; -.
DR   OrthoDB; EOG091G063Z; -.
DR   PhylomeDB; Q9Y5P4; -.
DR   TreeFam; TF106160; -.
DR   BRENDA; 2.7.11.9; 2681.
DR   Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis.
DR   SIGNOR; Q9Y5P4; -.
DR   EvolutionaryTrace; Q9Y5P4; -.
DR   GeneWiki; COL4A3BP; -.
DR   GenomeRNAi; 10087; -.
DR   PRO; PR:Q9Y5P4; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000113163; -.
DR   CleanEx; HS_COL4A3BP; -.
DR   ExpressionAtlas; Q9Y5P4; baseline and differential.
DR   Genevisible; Q9Y5P4; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0097001; F:ceramide binding; IDA:UniProtKB.
DR   GO; GO:0035620; F:ceramide transporter activity; IDA:UniProtKB.
DR   GO; GO:0070273; F:phosphatidylinositol-4-phosphate binding; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0000902; P:cell morphogenesis; IEA:Ensembl.
DR   GO; GO:0008283; P:cell proliferation; IEA:Ensembl.
DR   GO; GO:0006672; P:ceramide metabolic process; IEA:Ensembl.
DR   GO; GO:0007029; P:endoplasmic reticulum organization; IEA:Ensembl.
DR   GO; GO:0035621; P:ER to Golgi ceramide transport; IMP:UniProtKB.
DR   GO; GO:0003007; P:heart morphogenesis; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; NAS:UniProtKB.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0055088; P:lipid homeostasis; IEA:Ensembl.
DR   GO; GO:0070584; P:mitochondrion morphogenesis; IEA:Ensembl.
DR   GO; GO:0006936; P:muscle contraction; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; IEA:Ensembl.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; TAS:Reactome.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.530.20; -; 1.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR023393; START-like_dom.
DR   InterPro; IPR002913; START_lipid-bd_dom.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF01852; START; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00234; START; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS50848; START; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Coiled coil; Complete proteome;
KW   Cytoplasm; Disease mutation; Endoplasmic reticulum; Golgi apparatus;
KW   Lipid transport; Lipid-binding; Mental retardation; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transport.
FT   CHAIN         1    624       Collagen type IV alpha-3-binding protein.
FT                                /FTId=PRO_0000220665.
FT   DOMAIN       23    117       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      389    618       START. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00197}.
FT   COILED      263    303       {ECO:0000255}.
FT   MOTIF       321    327       FFAT.
FT   BINDING     472    472       Ceramide.
FT   BINDING     493    493       Ceramide.
FT   BINDING     530    530       Ceramide.
FT   BINDING     579    579       Ceramide.
FT   MOD_RES     126    126       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     132    132       Phosphoserine; by PKD.
FT                                {ECO:0000269|PubMed:17591919}.
FT   MOD_RES     135    135       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9EQG9}.
FT   MOD_RES     315    315       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983}.
FT   MOD_RES     372    372       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     373    373       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     377    377       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     380    380       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1      1       M -> MQHSCIPTPPSPFSAPPAFLPVVTRESRRGLSSGGS
FT                                AGRNAGVTATAAAADGWKGRLPSPLVLLPRSARCQARRRRG
FT                                GRTSSLLLLPPTPERALFASPSPDPSPRGLGASSGAAEGAG
FT                                AGLLLGCRASM (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041022.
FT   VAR_SEQ     371    396       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:11007769,
FT                                ECO:0000303|PubMed:14685229,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_006276.
FT   VARIANT     132    132       S -> L (in MRD34).
FT                                {ECO:0000269|PubMed:25533962}.
FT                                /FTId=VAR_073721.
FT   VARIANT     138    138       S -> C (found in a patient with mental
FT                                retardation).
FT                                {ECO:0000269|PubMed:23033978}.
FT                                /FTId=VAR_069403.
FT   VARIANT     599    599       K -> R (in dbSNP:rs55882089).
FT                                /FTId=VAR_061815.
FT   MUTAGEN     132    132       S->A: Abolishes the phosphorylation.
FT                                Strongly reduces the interaction with
FT                                phosphatidylinositol 4-phosphate.
FT                                Increases the ceramide transfer activity.
FT                                {ECO:0000269|PubMed:17591919}.
FT   MUTAGEN     324    324       D->A: Impairs the endoplasmic reticulum-
FT                                to-Golgi ceramide trafficking and
FT                                abolishes the interaction with VAPA.
FT                                {ECO:0000269|PubMed:16895911}.
FT   MUTAGEN     472    472       E->A: Reduces ceramide transfer.
FT                                {ECO:0000269|PubMed:18184806}.
FT   MUTAGEN     493    493       Q->A: No effect on ceramide transfer
FT                                activity. {ECO:0000269|PubMed:18184806}.
FT   MUTAGEN     499    499       W->A: Reduces affinity for membranes.
FT                                Abolishes ceramide transfer; when
FT                                associated with A-588.
FT                                {ECO:0000269|PubMed:20036255}.
FT   MUTAGEN     530    530       N->A: Reduces ceramide transfer.
FT                                {ECO:0000269|PubMed:18184806}.
FT   MUTAGEN     588    588       W->A: Abolishes ceramide transfer; when
FT                                associated with A-499.
FT   STRAND       26     33       {ECO:0000244|PDB:4HHV}.
FT   TURN         36     38       {ECO:0000244|PDB:4HHV}.
FT   STRAND       40     48       {ECO:0000244|PDB:4HHV}.
FT   STRAND       51     56       {ECO:0000244|PDB:4HHV}.
FT   STRAND       58     62       {ECO:0000244|PDB:4HHV}.
FT   STRAND       64     71       {ECO:0000244|PDB:4HHV}.
FT   STRAND       75     78       {ECO:0000244|PDB:4HHV}.
FT   STRAND       85     90       {ECO:0000244|PDB:4HHV}.
FT   STRAND       93     98       {ECO:0000244|PDB:4HHV}.
FT   HELIX       102    119       {ECO:0000244|PDB:4HHV}.
FT   HELIX       397    407       {ECO:0000244|PDB:2E3N}.
FT   STRAND      413    415       {ECO:0000244|PDB:2E3M}.
FT   STRAND      418    424       {ECO:0000244|PDB:2E3N}.
FT   STRAND      427    432       {ECO:0000244|PDB:2E3N}.
FT   STRAND      444    451       {ECO:0000244|PDB:2E3N}.
FT   HELIX       455    463       {ECO:0000244|PDB:2E3N}.
FT   HELIX       465    467       {ECO:0000244|PDB:2E3N}.
FT   HELIX       468    471       {ECO:0000244|PDB:2E3N}.
FT   STRAND      474    485       {ECO:0000244|PDB:2E3N}.
FT   STRAND      488    495       {ECO:0000244|PDB:2E3N}.
FT   STRAND      499    502       {ECO:0000244|PDB:3H3S}.
FT   STRAND      504    515       {ECO:0000244|PDB:2E3N}.
FT   STRAND      518    522       {ECO:0000244|PDB:2E3O}.
FT   STRAND      525    532       {ECO:0000244|PDB:2E3N}.
FT   STRAND      542    546       {ECO:0000244|PDB:2E3N}.
FT   STRAND      548    559       {ECO:0000244|PDB:2E3N}.
FT   STRAND      563    565       {ECO:0000244|PDB:3H3S}.
FT   HELIX       570    572       {ECO:0000244|PDB:2E3N}.
FT   STRAND      573    584       {ECO:0000244|PDB:2E3N}.
FT   HELIX       591    617       {ECO:0000244|PDB:2E3N}.
FT   STRAND      618    620       {ECO:0000244|PDB:2E3Q}.
SQ   SEQUENCE   624 AA;  70835 MW;  A125162492AC5A0E CRC64;
     MSDNQSWNSS GSEEDPETES GPPVERCGVL SKWTNYIHGW QDRWVVLKNN ALSYYKSEDE
     TEYGCRGSIC LSKAVITPHD FDECRFDISV NDSVWYLRAQ DPDHRQQWID AIEQHKTESG
     YGSESSLRRH GSMVSLVSGA SGYSATSTSS FKKGHSLREK LAEMETFRDI LCRQVDTLQK
     YFDACADAVS KDELQRDKVV EDDEDDFPTT RSDGDFLHST NGNKEKLFPH VTPKGINGID
     FKGEAITFKA TTAGILATLS HCIELMVKRE DSWQKRLDKE TEKKRRTEEA YKNAMTELKK
     KSHFGGPDYE EGPNSLINEE EFFDAVEAAL DRQDKIEEQS QSEKVRLHWP TSLPSGDAFS
     SVGTHRFVQK PYSRSSSMSS IDLVSASDDV HRFSSQVEEM VQNHMTYSLQ DVGGDANWQL
     VVEEGEMKVY RREVEENGIV LDPLKATHAV KGVTGHEVCN YFWNVDVRND WETTIENFHV
     VETLADNAII IYQTHKRVWP ASQRDVLYLS VIRKIPALTE NDPETWIVCN FSVDHDSAPL
     NNRCVRAKIN VAMICQTLVS PPEGNQEISR DNILCKITYV ANVNPGGWAP ASVLRAVAKR
     EYPKFLKRFT SYVQEKTAGK PILF
//
